尖吻蝮蛇血凝酶在神经外科术后应用的安全性评价

Safety research of haemocoagulase agkistrodon application after neurosurgery operation

目的评价注射用尖吻蝮蛇血凝酶(HCA)在神经外科手术中应用的安全性。方法选取2010年9月-2011年4月神经外科手术患者61例为研究对象,术后均给予HCA止血治疗。观察给药前和给药后第3天患者凝血功能、血常规、肝肾功能指标变化情况。结果 HCA用于神经外科手术止血,用药前与用药后第3天,患者生命体征、肝肾、心脏以及凝血功能,均未发生显著性变化,整个试验过程无不良反应。结论注射用HCA在神经外科手术中应用安全、有效。

Objective To evaluate the safety of hemocoagulase agkistrodon（ HCA） application in neurosurgery patients. Methods 61 cases of patients underwent neurosurgery operation from September 2010 to April 2011 were included in this clinical trial and they were administrated by HCA after surgery. Then,the coagulative function,blood routine test,hepatic and renal function before and 3 days after the operation were compared. Results There no significant difference in the vital sign,coagulative function,hemostatic function,hepatic and renal function values between before and 3 days after the operation when HCA was used in neurosurgery operation（ P〉0. 05）. There were no adverse events occurred. Conclusion Hemocoagulase agkistrodon is safe and effective in neurosurgery surgery.